First-generation protease inhibitor-triple therapy: SVR 24, safety, and predictors of response in a large single center cohort

Background/Aims Aim of this retrospective study was to analyze the efficacy, safety, and predictors of treatment success for first-generation-PI triple therapies, including either boceprevir or telaprevir, in a mono-centric “real-life” setting with respect to SVR 24.